Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Sweden
/
Pharmaceuticals & Biotech
/
Biovica International
BIOVIC B
Biovica International
Rising Reimbursement Cuts And Delays Will Weaken Market Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
19 Aug 25
Updated
19 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
SEK 0.60
7.3% overvalued
intrinsic discount
19 Aug
SEK 0.64
Loading
1Y
-76.6%
7D
-3.0%
Author's Valuation
SEK 0.6
7.3% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
SEK 0.6
7.3% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-167m
127m
2015
2017
2019
2021
2023
2025
2027
2028
Revenue SEK 126.6m
Earnings SEK 27.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
72.19%
Biotech revenue growth rate
12.78%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.92%
Calculation
SEK 27.01m
Earnings '28
x
3.18x
PE Ratio '28
=
SEK 85.92m
Market Cap '28
SEK 85.92m
Market Cap '28
/
123.99m
No. shares '28
=
SEK 0.69
Share Price '28
SEK 0.69
Share Price '28
Discounted to 2025 @ 4.92% p.a.
=
SEK 0.60
Fair Value '25
